News

US-based Scolr Pharma has reported a net loss of $2.92m, or $0.07 per share, for the fourth quarter of 2008, compared to a net loss of $3.52m, or

Intra-Cellular Therapies, a biopharmaceutical company, has announced positive final results from the ITI-007 Phase II trial in patients with sleep maintenance insomnia. This Phase II trial was a

Rigel Pharmaceuticals has announced the enrollment of the first patient in a Phase II, multi-center clinical trial of R788 in patients with refractory or relapsed peripheral T-cell lymphoma.

NPS Pharmaceuticals, a biopharmaceutical company engaged in the development of specialty therapeutics to treat gastrointestinal and endocrine disorders, has reported a net loss of $8.48m, or $0.18 per

According to Therative, ThermaClear is safe on all skin types and tones and does not cause the drying, irritation or skin hyper pigmentation often associated with many topical

These results are substantially in line with management expectations. They reflect budgeted sales and marketing initiatives to promote the Previstage GCC Colorectal Cancer Staging Test and further product

Progenics Pharmaceuticals, a biopharmaceutical company, has reported a net loss of $14.6m, or $0.49 per share, for the fourth quarter of 2008, compared to a net loss of

Persistent activation of the Akt pathway has been found to play an important role in oncogenesis and chemo- and radiation-resistance and to be responsible for cancer cell proliferation,

MLR-1023 was discovered and developed internally using Melior’s indications discovery platform, theraTRACE. Andrew Reaume, president and CEO of Melior, said: “We are delighted to have been given the